Kaskela Law LLC announces that it is investigating Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea”) on behalf of the company’s investors.

In November 2020, Atea completed its initial public offering (“IPO”) of common stock, selling 14.3 million shares of stock to investors at a price of $24.00 per share.  Subsequently, shares of the company’s stock traded as high as $86.00 per share in January 2021.  However, since that time, Atea’s shares have significantly declined in value to currently trade at less than $5.00 per share.

The investigation seeks to determine whether Atea and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to the company’s shareholders.

Atea shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by completing the form on this page, for additional information about this investigation and their legal rights and options.